NCT02042729View on ClinicalTrials.gov

A Phase 1 Comparative Study of E2022 Current and New Patch Formulations

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

December 31, 2012

Conditions
Healthy
Interventions
DRUG

E2022- Current Formula Tape

"Cohort I: E2022 current formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 current formula tape administered to skin application site and evaluated for 20 days."

DRUG

E2022- New Formula Tape

"Cohort I: E2022 new formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 new formula tape administered to skin application site and evaluated for 20 days."

DRUG

E2022 Matching Placebo- Current Formula Tape

DRUG

E2022 Matching Placebo- New Formula Tape

Trial Locations (1)

Unknown

Fukuoka

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT02042729 - A Phase 1 Comparative Study of E2022 Current and New Patch Formulations | Biotech Hunter | Biotech Hunter